Pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, combined with azacitidine in patients with AML-Reference-Cited by-同舟云学术

Pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, combined with azacitidine in patients with AML

Published:2018-03-29 Issue:13 Volume:131 Page:1415-1424
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Swords Ronan T.¹^ORCID,Coutre Steven²,Maris Michael B.³,Zeidner Joshua F.⁴^ORCID,Foran James M.⁵,Cruz Jose⁶^ORCID,Erba Harry P.⁷,Berdeja Jesus G.⁸,Tam Wayne⁹^ORCID,Vardhanabhuti Saran¹⁰^ORCID,Pawlikowska-Dobler Iwona¹⁰^ORCID,Faessel Hélène M.¹⁰,Dash Ajeeta B.¹⁰^ORCID,Sedarati Farhad¹⁰^ORCID,Dezube Bruce J.¹⁰^ORCID,Faller Douglas V.¹⁰^ORCID,Savona Michael R.¹¹^ORCID

Affiliation:

1. Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL;

2. Department of Medicine, Stanford University, Stanford, CA;

3. Colorado Blood Cancer Institute, Denver, CO;

4. Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC;

5. Mayo Clinic Cancer Center, Jacksonville, FL;

6. Texas Transplant Institute, San Antonio, TX;

7. UAB Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, AL;

8. Sarah Cannon Research Institute, Nashville, TN;

9. Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY;

10. Millennium Pharmaceuticals, Inc., Cambridge, MA; and

11. Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, TN

Abstract

Key Points RP2D of PEV 20 mg/m2 in PEV/AZA combo did not alter toxicity profile of AZA; dose-limiting toxicities were transiently elevated AST/ALT. In treatment-naive older AML patients, the intent-to-treat ORR was 50%.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/131/13/1415/1404456/blood805895.pdf

Reference64 articles.

1. The impact of dose escalation and resistance modulation in older patients with acute myeloid leukaemia and high risk myelodysplastic syndrome: the results of the LRF AML14 trial;Burnett;Br J Haematol,2009

2. A comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment;Burnett;Cancer,2007

3. European development of clofarabine as treatment for older patients with acute myeloid leukemia considered unsuitable for intensive chemotherapy;Burnett;J Clin Oncol,2010

4. How I treat acute myeloid leukemia presenting with preexisting comorbidities;Ofran;Blood,2016

5. How I treat acute myeloid leukemia;Rowe;Blood,2010

Cited by 170 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Inhibition of neddylation disturbs zygotic genome activation through histone modification change and leads to early development arrest in mouse embryos;Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease;2024-10

2. MLN4924 alleviates autoimmune myocarditis by promoting Act1 degradation and blocking Act1-mediated mRNA stability;International Immunopharmacology;2024-09

3. Ubiquitination and deubiquitination in cancer: from mechanisms to novel therapeutic approaches;Molecular Cancer;2024-07-25

4. Latent mitotic vulnerability of AML cells induced by therapeutic agents;2024-07-01

5. Loss of NEDD8 in cancer cells causes vulnerability to immune checkpoint blockade in triple-negative breast cancer;Nature Communications;2024-04-27